A Phase 1, Open-label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With High Risk (IPI 3 or More) Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3B Follicular Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs Azacitidine (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 07 Jun 2017 Biomarkers information updated
- 18 Jul 2016 Planned End Date changed from 1 Apr 2019 to 1 May 2017.
- 03 May 2016 Planned End Date changed from 1 Jun 2019 to 1 Apr 2019.